Blue Shield of California now covers the Renessa System (Novasys Medical, Inc., Newark, CA) treatment for non-pregnant women diagnosed with moderate to severe stress urinary incontinence who are unable or unwilling to undergo surgery.
Blue Shield of California now covers the Renessa System (Novasys Medical, Inc., Newark, CA) treatment for non-pregnant women diagnosed with moderate to severe stress urinary incontinence who are unable or unwilling to undergo surgery.
Blue Shield’s coverage policy follows the California Technology Assessment Forum’s review of Renessa, which met all five of its criteria for safety, effectiveness, and improvement in health outcomes in appropriately selected patients.
The FDA-cleared Renessa System includes a small probe that a physician inserts transurethrally. The probe gently heats the tissue in the bladder neck and upper urethra. The heat denatures the collagen in the tissue, and upon healing, the tissue becomes firmer and more resistant to leaks, according to Novasys.
EV/pembrolizumab under review in China for advanced urothelial carcinoma
March 28th 2024The sBLA is supported by findings from the phase 3 EV-302 trial, which showed that EV/pembrolizumab extended overall survival and progression-free survival vs platinum-based chemotherapy in patients with advanced urothelial carcinoma.
Potential code for prior authorizations on AMA CPT Editorial Panel meeting agenda
March 28th 2024"Good public and economic policy must align costs, benefits, and incentives; currently, all costs are incurred by physician practices, and all financial savings and benefits from prior authorization accrue to health insurance plans, leading to perverse incentives,” says Alex Shteynshlyuger, MD.